* Says goal is not to get acquired
* Says in acquiring mode
* Reaffirms co not looking for partner for Cinryze
* Does not see competition for Cinryze in near future
By Vidya L Nathan
BANGALORE, Aug 26 (Reuters) - ViroPharma Inc VPHM.O said it was not aiming to be acquired, responding to a market rumor that Israeli generic-drugmaker Teva Pharmaceutical Industries Ltd TEVA.TATEVA.O was looking to buy the company.
The takeover chatter sent the biopharmaceutical company’s shares up as much as 7 percent Wednesday on three times their 10-day average trading volume.
“It is certainly not the goal of the management team to be acquired at this point. We are looking to build the company,” ViroPharma spokesperson Robert Doody told Reuters by phone.
The company was looking to acquire products, he said.
“Our company has stated that we are more in the acquiring mode. And currently that is the focus of our management team.”
However, he said it would be the management’s duty to consider any offer on the table.
Teva Pharmaceutical was not immediately available for comment.
Doody reaffirmed ViroPharma was not looking to partner its drug, Cinryze, which is indicated to prevent attacks of a rare genetic disease called hereditary angioedema.
“Our product’s specific focus is on the prophylaxis indication and right now we don’t see anyone in the horizon who would be a viable competitor in the prophylaxis space,” he said.
The company was also not looking for partners for its experimental early stage drug to prevent relapse of a bacterial infection of the gut, he said.
Doody added that the company would consider a partnership if the offer was “overwhelming.”
Shares of the company closed up 4 percent at $8.43 Wednesday on Nasdaq. They had touched a high of $8.65 during the session. (Editing by Vinu Pilakkott)